ArticleMedComm2026
Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large-Cohort Study.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current methods for assessing treatment response and prognosis in pancreatic ductal adenocarcinoma (PDAC) have intrinsic limitations, necessitating novel biomarkers. This prospective cohort study evaluated whether early dynamic changes in ctDNA predict treatment efficacy and outcomes in advanced PDAC. We enrolled 127 patients receiving first-line therapy, with peripheral blood collected at baseline (B1), first response assessment (B2), and subsequent timepoints for high-depth next-generation sequencing. The ctDNA detection rates significantly decreased from 78.7% at B1 to 55.7% at B2. Elevated CA19-9 levels, ctDNA, and maximum somatic allele frequency (MSAF) were associated with disease progression. Higher B1 ctDNA and MSAF correlated with shorter progression-free survival (PFS) and overall survival (OS), consistent with an external validation cohort. The Cox regression confirmed that MSAF and CA19-9 were significant prognostic factors. In CA19-9-negative PDAC patients, increased ctDNA levels were associated with shorter PFS. This study demonstrated that high ctDNA levels and MSAF values are indicators of poor prognosis. Conversely, a decrease or clearance of ctDNA and MSAF suggests better disease control. In addition, in CA19-9-negative patients, dynamic ctDNA monitoring was able to indicate disease control and predict patient prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.